Health Trials

Menstrual Migraine

3

Review clinical trials related to Menstrual Migraine. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.

Participants needed: 723
Trial details
Phase: Phase 3Age: 18-45Biological sex: FemaleType: InterventionalSponsor: PfizerUpdated: Jun 10, 2026Locations: 123
Eligibility criteria

Participant has regular menstrual cycles ≥24 days and ≤34 days [+4]

Greater than 6 migraine days per month that are outside of the perimenstrual per... [+4]

Read more
Status: Not yet recruiting

Evaluation of the Migraceutics® Phase-Specific Dietary Supplement Regimen on Quality of Life, Work Productivity, and Biomarkers in Adult Migraineurs: The Migraceutics® START Study

The purpose of this study is to evaluate the impact of the Migraceutics® phase-specific dietary supplement regimen on quality of life, work productivity, and biomarkers in adult migraineurs.

Participants needed: 920
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: Miracle Wellness LLCUpdated: Jun 8, 2026Locations: 1
Eligibility criteria

Self-reported history of migraine, based on the International Headache Society (... [+3]

Pregnancy or lactation. [+5]

Read more
Status: Recruiting

Fremanezumab for the Prevention of Menstrually-related Migraine Attacks

The goal of this observational study is to compare, in real-world clinical practice, the effect of fremanezumab on menstrual migraine to the effect of fremanezumab on non-perimenstrual attacks. The main question it aims to answer is, if menstrually-related migraine attacks respond equally well to anti-CGRP mAb treatment with fremanezumab as non-menstrually-related attacks. Participants diagnosed with episodic or chronic migraine with menstrually-related migraine with or without aura and treated with fremanzumab according to the SmPC will be required to maintain a headache diary over at least 3 months prior to and 6 months after fremanezumab initiation.

Participants needed: 120
Trial details
Age: 18+Biological sex: FemaleType: ObservationalSponsor: Insel Gruppe AG, University Hospital BernUpdated: Oct 26, 2024Locations: 1
Eligibility criteria

Premenopausal women of 18 years of age or older. [+8]

Patients with pure menstrual migraine. [+6]

Read more